138.7K XNAS Volume
XNAS 28 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Matteo Levisetti | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Lucinda Warren | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Pasha Sarraf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 48,800 | 48,800 | - | - | Stock Option (right to buy) | |
| Frederick W. Driscoll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Pamela D. Garzone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Patrick Verheyen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| R. Daniel Passeri | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 1.03 per share. | 16 Dec 2024 | 30,000 | 164,578 (0%) | 0% | 1.0 | 30,900 | Common Stock |
| Baker G. Daniel | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Lucinda Warren | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 350,000 | 350,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Matteo Levisetti | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Matteo Levisetti | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 260,000 | 260,000 | - | - | Stock Option (right to buy) | |
| Levisetti Matteo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| A. Peter Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Patrick Verheyen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| D. Garzone Pamela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Frederick W. Driscoll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Purchase of securities on an exchange or from another person at price $ 2.76 per share. | 25 Aug 2023 | 4,000 | 135,638 (0%) | 0% | 2.8 | 11,040 | Common Stock |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 2.86 per share. | 14 Aug 2023 | 3,000 | 134,578 (0%) | 0% | 2.9 | 8,580 | Common Stock |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2023 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2023 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2023 | 113,000 | 113,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2023 | 124,125 | 124,125 | - | - | Stock Option (right to buy) | |
| Matteo Levisetti | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2023 | 82,500 | 82,500 | - | - | Stock Option (right to buy) | |
| Pamela D. Garzone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Patrick Verheyen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Sale of securities on an exchange or to another person at price $ 3.28 per share. | 23 Mar 2023 | 9,325 | 357 (0%) | 0% | 3.3 | 30,586 | Common Stock |
| Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 23 Mar 2023 | 9,682 | 9,682 (0%) | 0% | 2.9 | 27,691 | Common Stock |
| Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2023 | 9,682 | 96,062 | - | - | Stock Option (right to buy) | |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 324,000 | 324,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 124,000 | 124,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 125,500 | 125,500 | - | - | Stock Option (right to buy) | |
| Patricia Nasshorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 97,900 | 97,900 | - | - | Stock Option (right to buy) | |
| Matteo Levisetti | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Frederick W. Driscoll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Tamar D. Howson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Aaron G.L. Fletcher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2022 | 6,667 | 17,139 (0%) | 0% | - | Common Stock | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2022 | 6,667 | 0 | - | - | Restricted Stock Units | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.05 per share. | 21 Aug 2022 | 2,828 | 14,311 (0%) | 0% | 3.0 | 8,625 | Common Stock |
| Cameron Gray | Director | 14 Jun 2022 | 61,111 | 0 | - | - | Warrants | ||
| Cameron Gray | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 14 Jun 2022 | 51,562 | 687,049 (2%) | 0% | 3.2 | 164,998 | Common Stock |
| Cameron Gray | Director | 14 Jun 2022 | 61,111 | 738,611 (3%) | 0% | 2.7 | 165,000 | Common Stock | |
| Frank Morich | Director | Purchase of securities on an exchange or from another person at price $ 3.75 per share. | 27 May 2022 | 28,000 | 28,000 (0%) | 0% | 3.8 | 105,000 | Common Stock |
| Aaron G.L. Fletcher | Director | Purchase of securities on an exchange or from another person at price $ 3.34 per share. | 23 May 2022 | 55,000 | 940,000 (4%) | 0% | 3.3 | 183,700 | Common Stock |
| Aaron G.L. Fletcher | Director | Purchase of securities on an exchange or from another person at price $ 3.52 per share. | 23 May 2022 | 150,000 | 885,000 (3%) | 0% | 3.5 | 528,000 | Common Stock |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 75,000 | 173,700 (0%) | 0% | - | Common Stock | |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 31 Mar 2022 | 32,122 | 141,578 (0%) | 0% | 4.9 | 156,755 | Common Stock |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2022 | 10,000 | 131,578 (0%) | 0% | 0 | Common Stock | |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 75,000 | 0 | - | - | Restricted Stock Units | |
| Anish Suri | PRESIDENT AND CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 31 Mar 2022 | 7,068 | 103,638 (0%) | 0% | 4.9 | 34,492 | Common Stock |
| Anish Suri | PRESIDENT AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 16,668 | 0 | - | - | Restricted Stock Units | |
| Anish Suri | PRESIDENT AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 16,668 | 110,706 (0%) | 0% | - | Common Stock | |
| Aaron G.L. Fletcher | Director | Purchase of securities on an exchange or from another person at price $ 4.76 per share. | 31 Mar 2022 | 735,000 | 735,000 (3%) | 3% | 4.8 | 3,498,600 | Common Stock |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Patricia Nasshorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 16,667 | 16,667 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 21,333 | 21,333 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 82,000 | 82,000 | - | - | Stock Option (right to buy) | |
| Frederick W. Driscoll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Tamar D. Howson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Cameron Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Aaron G.L. Fletcher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 15 Nov 2021 | 18,815 | 18,815 (0%) | 0% | 2.9 | 53,811 | Common Stock |
| Peter A. Kiener | Director | Sale of securities on an exchange or to another person at price $ 17.92 per share. | 15 Nov 2021 | 18,815 | 0 (0%) | 0% | 17.9 | 337,165 | Common Stock |
| Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 15 Nov 2021 | 1,361 | 1,361 (0%) | 0% | 2.9 | 3,892 | Common Stock |
| Peter A. Kiener | Director | Sale of securities on an exchange or to another person at price $ 18.02 per share. | 15 Nov 2021 | 1,361 | 0 (0%) | 0% | 18.0 | 24,525 | Common Stock |
| Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 18,815 | 107,105 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 1,361 | 105,744 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 8,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 15 Nov 2021 | 8,000 | 94,038 (0%) | 0% | 18.1 | 144,400 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 15 Nov 2021 | 8,000 | 102,038 (0%) | 0% | 8.3 | 66,080 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 20,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 11 Nov 2021 | 20,000 | 94,038 (0%) | 0% | 15.1 | 301,354 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 11 Nov 2021 | 20,000 | 114,038 (0%) | 0% | 6.4 | 128,400 | Common Stock |
| Anish Suri | PRESIDENT AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2021 | 33,334 | 108,172 (0%) | 0% | - | Common Stock | |
| Anish Suri | PRESIDENT AND CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.97 per share. | 03 Oct 2021 | 14,134 | 94,038 (0%) | 0% | 13.0 | 183,318 | Common Stock |
| Anish Suri | PRESIDENT AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2021 | 33,334 | 0 | - | - | Restricted Stock Units | |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.57 per share. | 30 Sep 2021 | 31,677 | 98,700 (0%) | 0% | 14.6 | 461,534 | Common Stock |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2021 | 75,000 | 75,000 | - | - | Restricted Stock Units | |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2021 | 75,000 | 130,377 (0%) | 0% | - | Common Stock | |
| Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 14.72 per share. | 24 Sep 2021 | 3,400 | 55,377 (0%) | 0% | 14.7 | 50,051 | Common Stock |
| Anish Suri | PRESIDENT AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2021 | 20,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | PRESIDENT AND CSO | Sale of securities on an exchange or to another person at price $ 15.23 per share. | 23 Sep 2021 | 20,000 | 74,838 (0%) | 0% | 15.2 | 304,646 | Common Stock |
| Anish Suri | PRESIDENT AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 23 Sep 2021 | 20,000 | 94,838 (0%) | 0% | 6.4 | 128,400 | Common Stock |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.50 per share. | 23 Aug 2021 | 1,251 | 11,723 (0%) | 0% | 7.5 | 9,383 | Common Stock |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 23 Aug 2021 | 1,961 | 10,472 (0%) | 0% | 0 | Common Stock | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 6,667 | 12,433 (0%) | 0% | 0 | Common Stock | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 1,251 | 53,749 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 6,667 | 6,667 | - | - | Restricted Stock Units | |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.22 per share. | 23 Aug 2021 | 1,251 | 10,472 (0%) | 0% | 14.2 | 17,783 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 439 | 133,567 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 15 Mar 2021 | 13,000 | 15,000 (0%) | 0% | 5 | 65,000 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 15 Mar 2021 | 13,000 | 2,000 (0%) | 0% | 15.1 | 196,269 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 15 Mar 2021 | 439 | 2,439 (0%) | 0% | 5 | 2,195 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.09 per share. | 15 Mar 2021 | 439 | 2,000 (0%) | 0% | 15.1 | 6,626 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 13,000 | 134,006 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 16 Feb 2021 | 16,000 | 18,000 (0%) | 0% | 2.9 | 45,760 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 2,994 | 147,006 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,280 | 0 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 16,000 | 1,280 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.05 per share. | 16 Feb 2021 | 4,274 | 2,000 (0%) | 0% | 15.1 | 64,345 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 16 Feb 2021 | 2,994 | 6,274 (0%) | 0% | 5 | 14,970 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 16 Feb 2021 | 1,280 | 3,280 (0%) | 0% | 2.9 | 3,661 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.15 per share. | 16 Feb 2021 | 16,000 | 2,000 (0%) | 0% | 15.2 | 242,422 | Common Stock |
| Daniel R. Passeri | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, General Counsel and Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 20 Jan 2021 | 2,720 | 4,720 (0%) | 0% | 2.9 | 7,779 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 20 Jan 2021 | 2,720 | 2,000 (0%) | 0% | 15.1 | 40,980 | Common Stock |
| Kenneth J. Pienta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 2,720 | 17,280 | - | - | Stock Option (right to buy) | |
| Frederick W. Driscoll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Tamar D. Howson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Cameron Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Barry J. Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Aaron G.L. Fletcher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Aaron Fletcher | Director | Purchase of securities on an exchange or from another person at price $ 12.64 per share. | 24 Nov 2020 | 6,548 | 165,000 (0%) | 0% | 12.6 | 82,776 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2020 | 33,333 | 67,891 (0%) | 0% | - | Common Stock | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2020 | 33,333 | 33,334 | - | - | Restricted Stock Units | |
| Anish Suri | President and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.30 per share. | 03 Oct 2020 | 9,800 | 58,091 (0%) | 0% | 16.3 | 159,740 | Common Stock |
| Cameron Gray | Director | Purchase of securities on an exchange or from another person at price $ 15.30 per share. | 29 Sep 2020 | 5,000 | 677,500 (2%) | 0% | 15.3 | 76,500 | Common Stock |
| Cameron Gray | Director | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 29 Sep 2020 | 5,000 | 672,500 (2%) | 0% | 15 | 75,000 | Common Stock |
| Kerri-Ann Millar | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2020 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| Kerri-Ann Millar | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2020 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Aug 2020 | 1,900 | 5,766 (0%) | 0% | 0 | Common Stock | |
| Kerri-Ann Millar | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2020 | 6,666 | 13,334 | - | - | Restricted Stock Units | |
| Kerri-Ann Millar | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2020 | 6,666 | 7,666 (0%) | 0% | 0 | Common Stock | |
| Colin G. Sandercock | SVP, General Counsel and Sec | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 05 Aug 2020 | 13,374 | 17,125 (0%) | 0% | 20 | 267,480 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2020 | 13,374 | 130,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, General Counsel and Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.50 per share. | 05 Aug 2020 | 13,374 | 30,499 (0%) | 0% | 7.5 | 100,305 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 05 Aug 2020 | 800 | 35,358 (0%) | 0% | 6.4 | 5,136 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2020 | 800 | 145,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 05 Aug 2020 | 800 | 34,558 (0%) | 0% | 20.0 | 16,008 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Sale of securities on an exchange or to another person at price $ 20.05 per share. | 03 Aug 2020 | 201 | 17,125 (0%) | 0% | 20.0 | 4,030 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.50 per share. | 03 Aug 2020 | 6,425 | 23,550 (0%) | 0% | 7.5 | 48,188 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.50 per share. | 03 Aug 2020 | 201 | 17,326 (0%) | 0% | 7.5 | 1,508 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 03 Aug 2020 | 6,425 | 17,125 (0%) | 0% | 20 | 128,500 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 201 | 143,374 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, General Counsel and Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 6,425 | 143,575 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 2,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.26 per share. | 03 Aug 2020 | 2,000 | 36,558 (0%) | 0% | 8.3 | 16,520 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 03 Aug 2020 | 3,800 | 40,358 (0%) | 0% | 6.4 | 24,396 | Common Stock |
| Anish Suri | President and CSO | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 03 Aug 2020 | 5,800 | 34,558 (0%) | 0% | 20.0 | 116,058 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 03 Aug 2020 | 400 | 34,958 (0%) | 0% | 6.4 | 2,568 | Common Stock |
| Anish Suri | President and CSO | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 03 Aug 2020 | 400 | 34,558 (0%) | 0% | 20.1 | 8,056 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 3,800 | 146,200 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 400 | 145,800 | - | - | Stock Option (right to buy) | |
| Aaron Fletcher | Director | Purchase of securities on an exchange or from another person at price $ 25.24 per share. | 24 Jun 2020 | 2,953 | 158,452 (0%) | 0% | 25.2 | 74,534 | Common Stock |
| Aaron Fletcher | Director | Purchase of securities on an exchange or from another person at price $ 24.64 per share. | 24 Jun 2020 | 4,547 | 155,499 (0%) | 0% | 24.6 | 112,038 | Common Stock |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2020 | 1,200 | 1,200 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2020 | 16,666 | 39,912 (0%) | 0% | 0 | Common Stock | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2020 | 16,666 | 100,001 | - | - | Restricted Stock Units | |
| Anish Suri | President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 50,000 | 116,667 | - | - | Restricted Stock Units | |
| Anish Suri | President and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 31 Mar 2020 | 5,354 | 34,558 (0%) | 0% | 0 | Common Stock | |
| Kenneth J. Pienta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Daniel R. Passeri | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2020 | 150,000 | 150,000 | - | - | Restricted Stock Units | |
| Daniel R. Passeri | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2020 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, General Counsel and Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2020 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | VP-Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2020 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Steven McKnight | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2020 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Christopher A. Marlett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Frederick W. Driscoll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Cameron Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Barry J. Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 9,600 | 9,600 | - | - | Stock Option (right to buy) | |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Aaron Fletcher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Christopher A. Marlett | Director | Sale of securities on an exchange or to another person at price $ 15.71 per share. | 27 Dec 2019 | 9,000 | 0 (0%) | 0% | 15.7 | 141,390 | Common Stock |
| Christopher A. Marlett | Director | Sale of securities on an exchange or to another person at price $ 15.77 per share. | 27 Dec 2019 | 6,700 | 768,503 (3%) | 0% | 15.8 | 105,659 | Common Stock |
| Christopher A. Marlett | Director | Sale of securities on an exchange or to another person at price $ 17.24 per share. | 27 Dec 2019 | 9,000 | 775,203 (3%) | 0% | 17.2 | 155,160 | Common Stock |
| Christopher A. Marlett | Director | Sale of securities on an exchange or to another person at price $ 16.82 per share. | 23 Dec 2019 | 17,000 | 803,850 (3%) | 0% | 16.8 | 285,940 | Common Stock |
| Christopher A. Marlett | Director | Sale of securities on an exchange or to another person at price $ 17.53 per share. | 23 Dec 2019 | 19,647 | 784,203 (3%) | 0% | 17.5 | 344,412 | Common Stock |
| Christopher A. Marlett | Director | Other type of transaction at price $ 0.00 per share. | 17 Dec 2019 | 755,980 | 845,582 (3%) | 3% | 0 | Common Stock | |
| Christopher A. Marlett | Director | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 17 Dec 2019 | 4,000 | 820,850 (3%) | 0% | 17 | 68,000 | Common Stock |
| Christopher A. Marlett | Director | Sale of securities on an exchange or to another person at price $ 15.73 per share. | 17 Dec 2019 | 20,732 | 824,850 (3%) | 0% | 15.7 | 326,114 | Common Stock |
| Christopher A. Marlett | Director | Other type of transaction at price $ 0.00 per share. | 17 Dec 2019 | 1,007,973 | 0 (0%) | 4% | 0 | Common Stock | |
| Anish Suri | President and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.63 per share. | 01 Nov 2019 | 12,087 | 23,246 (0%) | 0% | 8.6 | 104,311 | Common Stock |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2019 | 33,333 | 66,667 | - | - | Restricted Stock Units | |
| Anish Suri | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2019 | 33,333 | 35,333 (0%) | 0% | 0 | Common Stock | |
| Anish Suri | President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2019 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2019 | 100,000 | 0 | - | - | Restricted Stock Units | |
| Aaron G.L. Fletcher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Daniel R. Passeri | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 7.26 per share. | 21 Jun 2019 | 1,377 | 51,977 (0%) | 0% | 7.3 | 9,997 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Purchase of securities on an exchange or from another person at price $ 7.90 per share. | 07 Jun 2019 | 15,025 | 17,125 (0%) | 0% | 7.9 | 118,698 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Purchase of securities on an exchange or from another person at price $ 7.35 per share. | 07 Jun 2019 | 100 | 2,100 (0%) | 0% | 7.4 | 735 | Common Stock |
| Daniel R. Passeri | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 6.90 per share. | 06 Jun 2019 | 3,000 | 50,600 (0%) | 0% | 6.9 | 20,700 | Common Stock |
| Daniel R. Passeri | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Daniel R. Passeri | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, General Counsel and Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Colin G. Sandercock | SVP, General Counsel and Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | VP-Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Anish Suri | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Bethany Mancilla | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Bethany Mancilla | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Anthony Digiandomenico | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Christopher A. Marlett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Frederick W. Driscoll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Steven McKnight | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Cameron Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Barry J. Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 9,600 | 9,600 | - | - | Stock Option (right to buy) | |
| Frank Morich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Christopher A. Marlett | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 9,000 | 1,007,973 (5%) | 0% | 0 | Common Stock | |
| Christopher A. Marlett | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 1,000 | 1,016,973 (5%) | 0% | 0 | Common Stock | |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 4.64 per share. | 31 Dec 2018 | 18,521 | 89,602 (0%) | 0% | 4.6 | 85,937 | Common Stock |
| Anthony Digiandomenico | None | Purchase of securities on an exchange or from another person at price $ 4.62 per share. | 28 Dec 2018 | 7,000 | 57,000 (0%) | 0% | 4.6 | 32,340 | Common Stock |
| Anthony Digiandomenico | None | Purchase of securities on an exchange or from another person at price $ 4.77 per share. | 27 Dec 2018 | 20,000 | 50,000 (0%) | 0% | 4.8 | 95,400 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 4.29 per share. | 26 Dec 2018 | 19,647 | 71,081 (0%) | 0% | 4.3 | 84,286 | Common Stock |
| Anthony Digiandomenico | None | Purchase of securities on an exchange or from another person at price $ 4.81 per share. | 24 Dec 2018 | 10,000 | 30,000 (0%) | 0% | 4.8 | 48,100 | Common Stock |
| Anthony Digiandomenico | None | Purchase of securities on an exchange or from another person at price $ 4.49 per share. | 21 Dec 2018 | 10,000 | 20,000 (0%) | 0% | 4.5 | 44,900 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 4.53 per share. | 21 Dec 2018 | 17,200 | 51,434 (0%) | 0% | 4.5 | 77,916 | Common Stock |
| Anish Suri | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 4.37 per share. | 21 Dec 2018 | 2,000 | 2,000 (0%) | 0% | 4.4 | 8,740 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 4.74 per share. | 20 Dec 2018 | 9,438 | 34,234 (0%) | 0% | 4.7 | 44,736 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 19 Dec 2018 | 400 | 24,796 (0%) | 0% | 5 | 2,000 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 18 Dec 2018 | 3,664 | 24,396 (0%) | 0% | 5.2 | 19,053 | Common Stock |
| Anthony Digiandomenico | None | Purchase of securities on an exchange or from another person at price $ 5.48 per share. | 17 Dec 2018 | 10,000 | 10,000 (0%) | 0% | 5.5 | 54,800 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 5.06 per share. | 13 Dec 2018 | 10,000 | 20,732 (0%) | 0% | 5.1 | 50,600 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 5.07 per share. | 12 Dec 2018 | 3,189 | 10,732 (0%) | 0% | 5.1 | 16,168 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 5.09 per share. | 12 Dec 2018 | 9,000 | 9,000 (0%) | 0% | 5.1 | 45,810 | Common Stock |
| Christopher A. Marlett | None | Purchase of securities on an exchange or from another person at price $ 4.86 per share. | 11 Dec 2018 | 7,543 | 7,543 (0%) | 0% | 4.9 | 36,659 | Common Stock |
| Kerri-Ann Millar | VP-Finance | Purchase of securities on an exchange or from another person at price $ 8.48 per share. | 29 Aug 2018 | 1,000 | 1,000 (0%) | 0% | 8.5 | 8,480 | Common Stock |
| Daniel R. Passeri | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 8.08 per share. | 16 Aug 2018 | 6,000 | 47,600 (0%) | 0% | 8.1 | 48,510 | Common Stock |
| Anish Suri | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Bethany Mancilla | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2018 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Frank Morich | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2018 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Ronald Seidel | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2018 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Rodolfo Chaparro | EVP, Head of Immunology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2018 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Kerri-Ann Millar | VP-Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2018 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Daniel R. Passeri | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 11.97 per share. | 29 Jun 2018 | 1,600 | 41,600 (0%) | 0% | 12.0 | 19,152 | Common Stock |
| Frederick W. Driscoll | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2018 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Anthony Digiandomenico | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2018 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Christopher A. Marlett | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2018 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Peter A. Kiener | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2018 | 9,600 | 9,600 | - | - | Stock Option (right to buy) | |
| Steven McKnight | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2018 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Cameron Gray | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2018 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Barry J. Simon | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2018 | 8,000 | 8,000 | - | - | Stock Option (Right to Buy) | |
| Anish Suri | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2018 | 250,000 | 250,000 | - | - | Stock Options | |
| Christopher A. Marlett | None | Other type of transaction at price $ 0.00 per share. | 29 Dec 2017 | 416,656 | 416,656 | - | - | Warrants | |
| Cameron Gray | None | Other type of transaction at price $ 0.00 per share. | 29 Dec 2017 | 192,495 | 192,495 | - | - | Warrants | |
| Christopher A. Marlett | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2017 | 833,312 | 833,312 | - | - | Warrants | |
| Kenneth J. Pienta | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 7.50 per share. | 27 Dec 2017 | 2,000 | 2,000 (0%) | 0% | 7.5 | 15,000 | Common Stock |
| Colin G. Sandercock | SVP, General Counsel and Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2017 | 150,000 | 150,000 | - | - | Stock Options |